NO172237C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater - Google Patents
Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivaterInfo
- Publication number
- NO172237C NO172237C NO874757A NO874757A NO172237C NO 172237 C NO172237 C NO 172237C NO 874757 A NO874757 A NO 874757A NO 874757 A NO874757 A NO 874757A NO 172237 C NO172237 C NO 172237C
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- tetrahydrone
- agency
- derivatives
- preparation
- Prior art date
Links
- -1 tri-substituted 2-imidazolyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 abstract 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Organic Insulating Materials (AREA)
- Luminescent Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH456586 | 1986-11-14 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO874757D0 NO874757D0 (no) | 1987-11-13 |
| NO874757L NO874757L (no) | 1988-05-16 |
| NO172237B NO172237B (no) | 1993-03-15 |
| NO172237C true NO172237C (no) | 1993-06-23 |
Family
ID=4278454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO874757A NO172237C (no) | 1986-11-14 | 1987-11-13 | Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater |
| NO1998001C NO1998001I1 (no) | 1986-11-14 | 1998-01-09 | Mibefradil |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1998001C NO1998001I1 (no) | 1986-11-14 | 1998-01-09 | Mibefradil |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US4808605A (cs) |
| EP (1) | EP0268148B1 (cs) |
| JP (1) | JP2504490B2 (cs) |
| KR (1) | KR960004863B1 (cs) |
| CN (1) | CN1028991C (cs) |
| AT (1) | ATE70267T1 (cs) |
| AU (1) | AU600769B2 (cs) |
| BG (1) | BG60937B2 (cs) |
| CA (1) | CA1319144C (cs) |
| CS (2) | CS264350B2 (cs) |
| DE (2) | DE19775076I2 (cs) |
| DK (1) | DK171349B1 (cs) |
| DZ (1) | DZ1142A1 (cs) |
| ES (1) | ES2040234T3 (cs) |
| FI (1) | FI94414C (cs) |
| GR (1) | GR3004029T3 (cs) |
| HK (1) | HK110494A (cs) |
| HU (1) | HU215915B (cs) |
| IE (1) | IE60695B1 (cs) |
| IL (1) | IL84407A (cs) |
| LV (1) | LV5745B4 (cs) |
| MC (1) | MC1883A1 (cs) |
| MX (1) | MX173614B (cs) |
| NL (1) | NL970019I2 (cs) |
| NO (2) | NO172237C (cs) |
| NZ (1) | NZ222474A (cs) |
| PH (1) | PH23919A (cs) |
| PT (1) | PT86130B (cs) |
| SG (1) | SG114194G (cs) |
| ZA (1) | ZA878362B (cs) |
| ZW (1) | ZW20087A1 (cs) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003283A1 (en) * | 1988-12-05 | 1990-06-05 | C. Anne Higley | Imidazoles for the treatment of atherosclerosis |
| CA2011461A1 (en) * | 1989-03-20 | 1990-09-20 | Urs Hengartner | Tetrahydronaphthalene derivatives |
| NL9001522A (nl) * | 1990-07-04 | 1992-02-03 | Schreiner Luchtvaart | Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen. |
| TW216770B (cs) * | 1991-07-23 | 1993-12-01 | Hoffmann La Roche | |
| US5663166A (en) * | 1991-10-18 | 1997-09-02 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| CA2205998C (en) * | 1994-11-23 | 2002-07-16 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| ATE215108T1 (de) | 1995-06-23 | 2002-04-15 | Univ Delft Tech | Verfahren zur herstellung eines schäumbaren filmes |
| TR199700018A2 (tr) * | 1996-01-31 | 1997-08-21 | Hoffmann La Roche | Alfa,beta-doymamis organik karboksilik asitlerin imaline yönelik proses. |
| US5811556A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via a naphthalenylacetic acid |
| US5808088A (en) * | 1997-04-30 | 1998-09-15 | Roche Colorado Corporation | Preparation of mibefradil via an acetamide anion |
| US5811557A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via an acetonitrile anion |
| US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
| US7101909B2 (en) * | 1998-10-12 | 2006-09-05 | Theravance, Inc. | Calcium channel drugs and uses |
| EP1493742A1 (en) * | 1999-07-28 | 2005-01-05 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| AU2001235364A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Tetrahydronaphtalene derivatives and their use |
| AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| DE60124616T2 (de) * | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors |
| FR2827862A1 (fr) * | 2001-07-27 | 2003-01-31 | Lipha | Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique |
| JP2005508949A (ja) * | 2001-10-10 | 2005-04-07 | アリックス セラピューティクス | 高血圧および狭心症の治療に有用なカルシウムチャネル遮断剤であるミベフラジルをベースとした化合物 |
| KR20030037081A (ko) * | 2001-11-02 | 2003-05-12 | 한국과학기술연구원 | Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법 |
| RS20050106A (sr) | 2002-08-19 | 2007-11-15 | Pfizer Products Inc., | Kombinovana terapija hiperproliferativnih bolesti |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| EP1660491B1 (en) * | 2003-07-28 | 2008-08-06 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| JP2008507585A (ja) * | 2004-07-26 | 2008-03-13 | コセリックス インク | 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療 |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2111863B1 (en) | 2005-10-26 | 2012-03-28 | Asahi Kasei Pharma Corporation | Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension |
| EP2351569B1 (en) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| HRP20140273T1 (hr) * | 2007-04-27 | 2014-04-25 | Actelion Pharmaceuticals Ltd. | Premošteni šesteroäślani prstenasti spojevi |
| AU2009234140B2 (en) * | 2008-04-11 | 2013-04-11 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| WO2009130679A1 (en) * | 2008-04-25 | 2009-10-29 | Actelion Pharmaceuticals Ltd | Benzimidazole derivatives as calcium channel blockers |
| KR20110079736A (ko) | 2008-10-22 | 2011-07-07 | 액테리온 파마슈티칼 리미티드 | 가교된 테트라하이드로나프탈렌 유도체 |
| WO2010046729A2 (en) * | 2008-10-23 | 2010-04-29 | Actelion Pharmaceuticals Ltd | Tetrahydronaphthalene compounds |
| CA2767646C (en) | 2009-07-10 | 2019-01-29 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| WO2011109464A1 (en) * | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012037665A1 (en) | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| US11273218B2 (en) | 2015-10-22 | 2022-03-15 | Cavion, Inc. | Methods for treating Angelman syndrome and related disorders |
| KR102642063B1 (ko) * | 2017-02-15 | 2024-03-04 | 카비온, 인코포레이티드 | 칼슘 채널 억제제 |
| JP7321097B2 (ja) | 2017-04-26 | 2023-08-04 | カビオン・インコーポレイテッド | 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法 |
| EP3860571A4 (en) | 2018-10-03 | 2022-06-29 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| CR20210441A (es) | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Inhibidores de la pcsk9 y métodos de uso de los mismos |
| CN115850119A (zh) * | 2022-11-26 | 2023-03-28 | 南昌大学 | 一种2-氯芳香胺类化合物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914216A (en) * | 1962-12-18 | 1975-10-21 | Boehringer Sohn Ingelheim | 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones |
| BE793460A (fr) * | 1971-12-29 | 1973-06-28 | Boehringer Sohn Ingelheim | Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h |
| NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
-
1987
- 1987-10-26 DK DK559987A patent/DK171349B1/da not_active IP Right Cessation
- 1987-10-26 CA CA000550190A patent/CA1319144C/en not_active Expired - Fee Related
- 1987-11-03 CS CS877874A patent/CS264350B2/cs not_active IP Right Cessation
- 1987-11-03 ZW ZW200/87A patent/ZW20087A1/xx unknown
- 1987-11-04 DE DE1997175076 patent/DE19775076I2/de active Active
- 1987-11-04 DE DE8787116251T patent/DE3775177D1/de not_active Expired - Lifetime
- 1987-11-04 EP EP87116251A patent/EP0268148B1/de not_active Expired - Lifetime
- 1987-11-04 ES ES198787116251T patent/ES2040234T3/es not_active Expired - Lifetime
- 1987-11-04 AT AT87116251T patent/ATE70267T1/de active
- 1987-11-06 NZ NZ222474A patent/NZ222474A/xx unknown
- 1987-11-06 ZA ZA878362A patent/ZA878362B/xx unknown
- 1987-11-09 AU AU80909/87A patent/AU600769B2/en not_active Ceased
- 1987-11-09 IL IL84407A patent/IL84407A/xx unknown
- 1987-11-10 US US07/119,114 patent/US4808605A/en not_active Expired - Lifetime
- 1987-11-10 JP JP62282287A patent/JP2504490B2/ja not_active Expired - Lifetime
- 1987-11-11 HU HU875011A patent/HU215915B/hu not_active IP Right Cessation
- 1987-11-11 PH PH36056A patent/PH23919A/en unknown
- 1987-11-11 DZ DZ870191A patent/DZ1142A1/fr active
- 1987-11-12 MC MC871928A patent/MC1883A1/xx unknown
- 1987-11-12 MX MX009271A patent/MX173614B/es unknown
- 1987-11-13 IE IE307087A patent/IE60695B1/en not_active IP Right Cessation
- 1987-11-13 KR KR87012777A patent/KR960004863B1/ko not_active Expired - Fee Related
- 1987-11-13 CN CN87107875A patent/CN1028991C/zh not_active Expired - Fee Related
- 1987-11-13 NO NO874757A patent/NO172237C/no not_active IP Right Cessation
- 1987-11-13 FI FI875024A patent/FI94414C/fi not_active IP Right Cessation
- 1987-11-13 PT PT86130A patent/PT86130B/pt not_active IP Right Cessation
-
1991
- 1991-12-20 CS CS913948A patent/CS394891A3/cs unknown
-
1992
- 1992-03-11 GR GR920400420T patent/GR3004029T3/el unknown
-
1994
- 1994-02-14 BG BG098469A patent/BG60937B2/bg unknown
- 1994-08-13 SG SG114194A patent/SG114194G/en unknown
- 1994-10-12 HK HK110494A patent/HK110494A/xx not_active IP Right Cessation
-
1996
- 1996-05-24 LV LV960155A patent/LV5745B4/xx unknown
-
1997
- 1997-05-27 NL NL970019C patent/NL970019I2/nl unknown
-
1998
- 1998-01-09 NO NO1998001C patent/NO1998001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO172237C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalinderivater | |
| NO176356C (no) | Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser | |
| NO168300C (no) | Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive imidazoliumsalter | |
| NO941977L (no) | Indolderivater, fremgangsmåte for fremstilling av disse, og medisinsk anvendelse derav | |
| NO161971C (no) | Analogifremgangsmaate ved fremstilling av tetrahydronaftalinderivater. | |
| NO881835L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser. | |
| KR890014112A (ko) | 퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도 | |
| IE44154L (en) | 1,3,8-triazaspiro(4,5) decan-4-one derivatives | |
| NO171639C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolpyrazolderivater | |
| NO863996D0 (no) | Nye 2-(2-tienyl)-imidazo(4,5-c)pyridinderivater og salter derav og fremgangsmaate til fremstilling av derivatene. | |
| NO177786B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater | |
| JPS57131788A (en) | 1,7-naphthyridine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MAY 2003 |